share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali

CRISPR Therapeutics | 4：持股變動聲明-董事 Behbahani Ali
美股sec公告 ·  06/01 04:54
牛牛AI助理已提取核心訊息
In a recent transaction, Ali Behbahani, a reporting person for CRISPR Therapeutics AG (CRSP), executed a stock transaction on May 30, 2024. The details of the transaction, including the number of shares involved, the nature of the shares, the transaction price, and the total value of the shares, were not disclosed. The relationship of Behbahani to the issuer was not specified in the announcement. Investors are advised to note the date of the transaction for any potential impact on the stock's performance.
In a recent transaction, Ali Behbahani, a reporting person for CRISPR Therapeutics AG (CRSP), executed a stock transaction on May 30, 2024. The details of the transaction, including the number of shares involved, the nature of the shares, the transaction price, and the total value of the shares, were not disclosed. The relationship of Behbahani to the issuer was not specified in the announcement. Investors are advised to note the date of the transaction for any potential impact on the stock's performance.
在最近的一筆交易中，CRISPR Therapeutics AG（CRSP）的舉報人阿里·貝巴哈尼於2024年5月30日執行了一筆股票交易。該交易的細節，包括所涉及的股票數量、股票的性質、交易價格和股票的總價值，尚未披露。公告中沒有具體說明Behbahani與發行人的關係。建議投資者注意交易日期，以了解對股票表現的任何潛在影響。
在最近的一筆交易中，CRISPR Therapeutics AG（CRSP）的舉報人阿里·貝巴哈尼於2024年5月30日執行了一筆股票交易。該交易的細節，包括所涉及的股票數量、股票的性質、交易價格和股票的總價值，尚未披露。公告中沒有具體說明Behbahani與發行人的關係。建議投資者注意交易日期，以了解對股票表現的任何潛在影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。